Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer
Benjamin L. Maughan(Huntsman Cancer Institute), Emmanuel S. Antonarakis(University of Minnesota), Mario A. Eisenberger(Johns Hopkins University), Rana Harb(Sidney Kimmel Comprehensive Cancer Center), Daniel L. Suzman(United States Food and Drug Administration), Rana Sullivan(Sidney Kimmel Comprehensive Cancer Center), Robert M. Hughes(Johns Hopkins University), Hao Wang(University of Mississippi), Angelo M. De Marzo(Johns Hopkins University), Channing J. Paller(Johns Hopkins University), Brandon Luber(Johns Hopkins University), Stephanie Glavaris(Johns Hopkins University), Karim Boudadi(Sidney Kimmel Comprehensive Cancer Center), Ashely Ross(Sidney Kimmel Comprehensive Cancer Center)
Cited by 31
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k